GAMMA Investing
IKT icon

GAMMA Investing’s Inhibikase Therapeutics IKT Stock Holding History

GAMMA Investing’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$510 Buy
+248
New +$564 ﹤0.01% 4208
2026
Q2 		– Sell
-411
Closed -$690 – 4190
2026
Q1 		$690 Buy
+411
New +$730 ﹤0.01% 3901

Other funds holding IKT

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Kennondale Capital Management
Kennondale Capital Management Richmond, Virginia $154M AUM 37.2% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.6B AUM 22.09% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

GAMMA Investing's IKT Position: Q3 2026 in Review

GAMMA Investing opened a new position in Inhibikase Therapeutics (IKT) in Q3 2026: 248 shares worth $510. The stake represents ﹤0.01% of the portfolio and ranks #4208 among its holdings. This is a return to the name: GAMMA Investing previously reported a position in IKT as recently as Q1 2026.

GAMMA Investing first reported a position in IKT in Q1 2026 and has held it in 2 quarters since. The position peaked at $690 in Q1 2026. 38 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • GAMMA Investing held 248 shares of Inhibikase Therapeutics worth $510 as of Q3 2026.
  • Inhibikase Therapeutics was a new GAMMA Investing position in Q3 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #4208 holding.
  • GAMMA Investing first reported a position in Inhibikase Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • GAMMA Investing's Inhibikase Therapeutics position peaked at $690 in Q1 2026.
  • 38 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.